Enanta Pharmaceuticals, Inc last reported quarterly results on Aug 10, 2026, for Q3 FY2026 (the quarter ended Jun 30, 2026): revenue of $14.4 million (-21.6% year over year) and diluted EPS of -$0.67. It usually reports 40–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 16, 2026.
Results for Q4 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 17, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 40–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q3 FY2026
ended Jun 30, 2026
|
14
-21.6%
|
-20
-6.8%
|
-0.67
+21.2%
|
|
May 11, 2026
41 days after quarter end
|
Q2 FY2026
ended Mar 31, 2026
|
17
+15.0%
|
-13
+42.2%
|
-0.45
+57.5%
|
|
Feb 9, 2026
40 days after quarter end
|
Q1 FY2026
ended Dec 31, 2025
|
19
|
-12
|
-0.42
|
|
Nov 17, 2025
48 days after quarter end
|
Q4 FY2025
ended Sep 30, 2025
|
15
+3.5%
|
-19
+35.1%
|
0.30
-35.4%
|
|
Aug 11, 2025
42 days after quarter end
|
Q3 FY2025
ended Jun 30, 2025
|
18
+1.9%
|
-18
+19.4%
|
-0.85
+20.6%
|
|
May 12, 2025
42 days after quarter end
|
Q2 FY2025
ended Mar 31, 2025
|
15
-12.5%
|
-23
+27.3%
|
-1.06
+27.9%
|
|
Feb 10, 2025
41 days after quarter end
|
Q1 FY2024
ended Dec 31, 2024
|
17
-28.1%
|
-22
+23.1%
|
-1.05
+24.5%
|
|
Nov 25, 2024
56 days after quarter end
|
Q4 FY2024
ended Sep 30, 2024
|
15
-22.8%
|
-29
-2.5%
|
0.46
+1.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENTA (Nasdaq)
- Fiscal year ends
- September 30
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1177648
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.